- NASDAQ:BNGO added 9.85% on Wednesday as the broader markets enjoyed a rare day in the green.
- BioNano’s Saphyr system has been adopted by two major labs in the U.K. which are owned by NHS.
- BNGO is ramping up its development as it plans to release the prototype for its next generation of Saphyr later this year.
Update April 24: BioNano Genomics Inc (NASDAQ: BNGO) shares have kicked off Thursday's session with an increase of nearly 10% to around $6.50. As detailed below, the gene-related company is venturing into the British market and that provides fresh prospects for higher incomes. The gains recorded on Thursday complete a third consecutive day of gains after BNGO shares lost ground throughout most of April.
NASDAQ:BNGO was a Wall Street darling in 2020, as the company based out of San Diego, California was pegged by many to be one of the next big genomics stocks to buy. But since BioNano’s Saphyr platform stole the show at the Cytogenomics symposium earlier this year, shares have nosedived losing nearly 60% of its price. On Wednesday BioNano gained 9.85% to close the trading session at $5.91, as the broader markets rallied following weeks of choppiness.
Stay up to speed with hot stocks' news!
The main catalyst for BioNano’s surge was the announcement that its Saphyr genome mapping platform has been adopted in two major U.K. labs that belong to the National Health System. The agency is using Saphyr to accurately map the genomes of patients with conditions such as heme malignancies, developmental delay, infertility, and other potential genetic diseases. These are just the latest cases of a successful year for Saphyr, which saw its sales grow year over year from 73 in 2019 to 97 in 2020. BioNano has already given guidance for 2021 sales and it expects another rise in Saphyr sales from 97 to 150.
BNGO Stock news
As the original Saphyr platform is ramping up, BioNano has already announced that the next-generation version will have a prototype ready by the end of 2021. It is anticipated that the updated version will be capable of handling fourteen times the amount of genomes analyzed and should revolutionize the way that pediatric and prenatal health can be monitored, right from birth.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD risks a deeper drop in the short term
AUD/USD rapidly left behind Wednesday’s decent advance and resumed its downward trend on the back of the intense buying pressure in the greenback, while mixed results from the domestic labour market report failed to lend support to AUD.
EUR/USD leaves the door open to a decline to 1.0600
A decent comeback in the Greenback lured sellers back into the market, motivating EUR/USD to give away the earlier advance to weekly tops around 1.0690 and shift its attention to a potential revisit of the 1.0600 neighbourhood instead.
Gold is closely monitoring geopolitics
Gold trades in positive territory above $2,380 on Thursday. Although the benchmark 10-year US Treasury bond yield holds steady following upbeat US data, XAU/USD continues to stretch higher on growing fears over a deepening conflict in the Middle East.
Bitcoin price shows strength as IMF attests to spread and intensity of BTC transactions ahead of halving
Bitcoin (BTC) price is borderline strong and weak with the brunt of the weakness being felt by altcoins. Regarding strength, it continues to close above the $60,000 threshold for seven weeks in a row.
Is the Biden administration trying to destroy the Dollar?
Confidence in Western financial markets has already been shaken enough by the 20% devaluation of the dollar over the last few years. But now the European Commission wants to hand Ukraine $300 billion seized from Russia.